News | February 21, 2024
AstraZeneca completes acquisition of Icosavax
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Submission to be reviewed under FDA real-time oncology review and Project Orbis
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subscribe To Our Newsletter & Stay Updated
